Evidence map›Paper›PMID 32735501›Full record

Trial reportThe Journal of international medical research2020

Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF-

Jinzhong Huang, Wei Hong, Zhilong Yang, Jian Ding, Yi Ren

RetractedOpen access · goldAbstract readRandomized Controlled TrialRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Inflammatory markers and depression in Parkinson's disease: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

  • Retraction · 2024-01-13Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Third Party Involvement · Investigation by Journal/Publisher · Paper Mill · Unreliable Results and/or Conclusions ·
  • Retracted
5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jinzhong HuangDepartment of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Wei HongDepartment of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Zhilong YangDepartment of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Jian DingDepartment of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Yi RenDepartment of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.ORCID https://orcid.org/0000-0002-0687-6201
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the efficacy of combining the dopamine receptor agonist pramipexole with levodopa for Parkinson's disease (PD) treatment and to measure their effects on quality of life and tumor necrosis factor (TNF)-α levels in PD patients. BASIC PROCEDURE: In total, 160 PD patients who were admitted to our hospital were equally randomized into a control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa). Both groups were treated for 12 weeks.

findingsAfter treatment, scores from the Unified Parkinson's Disease Rating Scales (1-3), the Hamilton Depression Scale, and the Parkinson's Disease Questionnaire (PDQ-39) were significantly decreased in both groups, whereas Mini-Mental State Examination scores were significantly increased. After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group. The incidence of adverse reactions was significantly lower in the study group than in the control group. Furthermore, after treatment, serum TNF-α levels were significantly decreased in both groups compared with pre-treatment levels.

conclusionPramipexole combined with levodopa relieved PD symptoms and improved the quality of life of PD patients, potentially by suppressing serum TNF-α levels.

Indexed as

LevodopaParkinson DiseaseAntiparkinson AgentsBenzothiazolesHumansPramipexoleQuality of LifeTumor Necrosis Factor-alphaAntiparkinson AgentsBenzothiazolesLevodopaPramipexoleTumor Necrosis Factor-alphadopamine receptor agonistlevodopaParkinson’s diseasepramipexolequality of lifetumor necrosis factor-α

Identifiers

PMID32735501
PMCPMC7401155
OpenAlexW3046869259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.